<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00483756</url>
  </required_header>
  <id_info>
    <org_study_id>A3921030</org_study_id>
    <nct_id>NCT00483756</nct_id>
  </id_info>
  <brief_title>Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients</brief_title>
  <official_title>A Phase 2 Randomized, Multicenter, Active Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Co-administration of CP-690,550 and Mycophenolate Mofetil / Mycophenolate Sodium in De Novo Renal Allograft Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune
      system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this
      research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant
      patients for 12 months. Patients will be assigned to one of three treatment groups after
      receiving a kidney transplant. Two of the treatment groups will receive 2 different dosing
      regimens of the JAK3 inhibitor that will be taken by mouth. The third treatment group will be
      a standard-of-care control arm. Patients will continue to take the assigned study medication
      for 12 months as well as other standard transplant medications such as prednisone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With First Clinical Biopsy Proven Acute Rejection (BPAR) Episode 6 Months Post-Transplant</measure>
    <time_frame>Baseline up to Month 6</time_frame>
    <description>Clinical BPAR was a BPAR (category acute rejection as interpreted by the central blinded pathologist according to the Banff 97 working classification) associated with an increase in serum creatinine of &gt;= 0.3 milligram per deciliter (mg/dL) and &gt;=20 percent (%) from pre-rejection baseline. The increase in serum creatinine was assessed based on the comparison of baseline and the highest serum creatinine recorded within 24 hours (hrs) of the time of biopsy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glomerular Filtration Rate (GFR) at Month 12</measure>
    <time_frame>2, 3, 4, and 5 hrs post iohexol intravenous bolus at Month 12</time_frame>
    <description>GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using iohexol serum clearance. For determination of iohexol serum clearance, iohexol was administered as an intravenous bolus over 5 minutes immediately after morning dosing of CP-690,550 or CsA on day of GFR evaluation. A normal GFR is greater than (&gt;) 90 milliliter per minute (mL/min), although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR less than (&lt;) 15 mL/min indicated kidney failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glomerular Filtration Rate (GFR) at Month 6</measure>
    <time_frame>2, 3, 4, and 5 hrs post iohexol intravenous bolus at Month 6</time_frame>
    <description>GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using iohexol serum clearance. For determination of iohexol serum clearance, iohexol was administered as an intravenous bolus over 5 minutes immediately after morning dosing of CP-690,550 or CsA on day of GFR evaluation. A normal GFR is &gt;90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR &lt;15 mL/min indicated kidney failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Progression of Chronic Allograft Lesions at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Progression of chronic allograft lesions was defined as an increase in the Banff chronicity score (Banff-CS) in biopsy from the implantation (baseline) biopsy in a given participant. Banff-CS was the sum of the Banff scores for the 4 chronic basic lesions (allograft glomerulopathy [cg] + interstitial fibrosis [ci] + tubular atrophy [ct] + vascular intimal thickening [cv]).The Banff-CS ranged from 0-12, higher score indicated greater lesions and Month 12 Banff-CS greater than the implantation biopsy score indicated progression of lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Clinical Biopsy Proven Acute Rejection (BPAR) 12 Months Post Transplant</measure>
    <time_frame>Baseline up to Month 12</time_frame>
    <description>Clinical BPAR was a BPAR (category acute rejection as interpreted by the central blinded pathologist according to the Banff 97 working classification) associated with an increase in serum creatinine of &gt;= 0.3 mg/dL and &gt;=20% from pre-rejection baseline. The increase in serum creatinine was assessed based on the comparison of baseline and the highest serum creatinine recorded within 24 hrs of the time of biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treated Clinical Acute Rejection</measure>
    <time_frame>Month 6, 12</time_frame>
    <description>Treated clinical acute rejection was defined as an acute rejection episode that was diagnosed based on local biopsy readout and received anti-rejection treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Combined Banff Rejection Categories (Categories 2, 3, and 4)</measure>
    <time_frame>Month 6, 12</time_frame>
    <description>Banff 97: standard classification for scoring and classifying rejection of kidney transplant biopsies in 6 diagnostic categories: normal, antibody-mediated rejection, borderline changes: 'suspicious' for acute cellular rejection, acute/active cellular rejection, chronic/sclerosing allograft nephropathy, and other. Combined Banff rejection calculated from categories of antibody-mediated rejection (Category 2) plus borderline changes (Category 3) plus acute rejection (Category 4), as interpreted by the central pathologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Graft Loss</measure>
    <time_frame>Month 6, 12</time_frame>
    <description>Graft loss was defined as graft nephrectomy, participant death, re-transplantation, or return to dialysis for &gt;=6 consecutive weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Efficacy Failure</measure>
    <time_frame>Month 6, 12</time_frame>
    <description>Efficacy failure was the first occurrence of clinical BPAR diagnosed by the central pathologist or graft loss including participant death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died</measure>
    <time_frame>Month 6, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte Subset</measure>
    <time_frame>Month 1, 3, 6, 12</time_frame>
    <description>The absolute cell counts of cluster of differentiation 3 (CD3): T-lymphocytes, cluster of differentiation 19 (CD19): B-lymphocytes, and cluster of differentiation 56 (CD56): assumed natural killer cells, were determined using flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population Pharmacokinetics (PK)</measure>
    <time_frame>Pre-dose-2(P-2), Pre-dose(P), 0.5,1,2 hr post-dose(PD) on Day14, Month(M) 3; P,1,2 hr PD on M1; P, 0.5, 2, 4 hr PD on M6; P-2, P, 0.5 hr PD on M9, M12 as per randomization in CP-690,550 treated; P on M3 and P, 2, 4 hr PD on M6 in CsA treated participants</time_frame>
    <description>Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular Filtration Rate (GFR) by The Nankivell Equation</measure>
    <time_frame>Month 1, 3, 6, 9, 12</time_frame>
    <description>GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated was estimated by creatinine clearance (CLcr) using Nankivell equation. CLcr by Nankivell equation= (6.7 per serum creatinine) plus (0.25*body weight) minus (0.5*serum urea) minus (100 per height square) plus (35 for male/25 for female). A normal GFR is &gt;90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR &lt;15 mL/min indicated kidney failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular Filtration Rate (GFR) by The Cockcroft-Gault Equation</measure>
    <time_frame>Month 1, 3, 6, 9, 12</time_frame>
    <description>GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated using Cockcroft-Gault equation. GFR by Cockcroft-Gault equation= body weight*(140 minus age in years) divided by (72*serum creatinine). For females value obtained was multiplied by 0.85. A normal GFR is &gt;90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR &lt;15 mL/min indicated kidney failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular Filtration Rate (GFR) by The Modification of Diet in Renal Disease (MDRD) Equation</measure>
    <time_frame>Month 1, 3, 6, 9, 12</time_frame>
    <description>GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using MDRD equation. GFR by MDRD equation = 170 * (serum creatinine)^(-0.999) * (age in years)^(-0.176) * (0.762 if female) * (1.18 if black) * (blood urea nitrogen concentration)^(-0.170) * (serum albumin concentration)^(0.318).A normal GFR is &gt;90 mL/min/1.73 square meter (m^2), although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR &lt;15 mL/min/1.73 m^2 indicated kidney failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular Filtration Rate (GFR) by The Abbreviated Modification of Diet in Renal Disease (MDRD) Equation</measure>
    <time_frame>Month 1, 3, 6, 9, 12</time_frame>
    <description>GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated using abbreviated MDRD equation. GFR by abbreviated MDRD equation= 186 * (serum creatinine)^(-1.154) * (age in years)^(-0.203) * (0.742 if female) * (1.210 if black). A normal GFR is &gt;90 mL/min/1.73 m^2, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR &lt;15 mL/min/1.73 m^2 indicated kidney failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Infections</measure>
    <time_frame>Baseline up to Month 12</time_frame>
    <description>Clinically significant infection was defined as the presence of documented infection confirmed by culture, biopsy, genomic, or serologic findings post-randomization and requiring hospitalization or parenteral anti-infective treatment, or otherwise deemed significant by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-Item Short-Form Health Survey (SF-36)</measure>
    <time_frame>Baseline, Month 6, 12</time_frame>
    <description>SF-36: standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as physical and mental component scores. Total of 11 variables were analyzed (8 subscales,2 composite subscales and Question(Q) 2 &quot;how would you rate your health in general now?&quot;(range 1=better, 5=worst). The score for a section (except Q2) is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-Stage Renal Disease Symptom Checklist Transplantation Module (ESRD-SCL)</measure>
    <time_frame>Baseline, Month 6, 12</time_frame>
    <description>ESRD-SCL:43-item disease specific self-administered questionnaire. Participants' rated question&quot;At the moment,how much do you suffer?&quot;for each item on 5 point scale,ranged (Ra) 0(not at all)to 4(extremely).Consisted of 6 subscales:cardiac and renal dysfunction;Ra 0-28,increased(In) growth of gum and hair;Ra 0-20,limited cognitive capacity;Ra 0-32,limited physical capacity;Ra 0 - 40,side effects (SEs) of corticosteroids;Ra 0-20,transplantation associated psychological distress(TAPD);Ra 0-32(higher scores=greater dysfunction for each subscale).Total score:0-172,higher scores=greater dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Dyspepsia Assessment (SODA)</measure>
    <time_frame>Baseline, Month 6, 12</time_frame>
    <description>SODA:17-item health scale, assessed participant-reported perceptions of dyspepsia;consists of 3 subscales:Pain Intensity (6-items to assess pain and intensity of abdominal [Ab] discomfort; Range (Ra):2-47, higher score= greater pain and Ab discomfort), Non-Pain Symptoms (7-items to assess severity and impact of non-pain symptoms:burping/belching,heartburn,bloating,flatulence,sour taste,nausea,and bad breath; Ra:7-35,higher scores = increased symptom severity and influence), and Satisfaction (4-items to assess degree of satisfaction with Ab discomfort; Ra:2-23,higher scores= more satisfaction).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">338</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment Arm 1 will also receive standard of care medications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Arm 2 will also receive standard of care medications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Arm 3 will also receive standard of care medications</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>CP-690,550 15 mg BID for Months 1-6, then 10 mg BID for Months 7-12</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>CP-690,550 15 mg BID for Months 1-3, then 10 mg BID for Months 4-12</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recipient of a first-time kidney transplant

          -  Between the ages of 18 and 70 years, inclusive

        Exclusion Criteria:

          -  Recipient of any non-kidney transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Anderlecht</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04038-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04039-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 21</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paris Cedex 15</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-006</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-417</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1069-166</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921030&amp;StudyName=Study%20of%20a%20JAK3%20Inhibitor%20for%20the%20Prevention%20of%20Acute%20Rejection%20in%20Kidney%20Transplant%20Patients</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2007</study_first_submitted>
  <study_first_submitted_qc>June 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2007</study_first_posted>
  <results_first_submitted>December 3, 2012</results_first_submitted>
  <results_first_submitted_qc>February 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 14, 2013</results_first_posted>
  <disposition_first_submitted>March 24, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>March 24, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 1, 2011</disposition_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunosuppression</keyword>
  <keyword>JAK3 inhibitor</keyword>
  <keyword>kidney transplantation.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Initially 7 participants were enrolled and randomized under original protocol but enrollment was terminated because 2 participants developed Grade 2B rejection. Protocol amendment 1 was implemented to increase aggregate level of immunosuppression and 331 participants were enrolled. Results of participants enrolled under amendment 1 are reported.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cyclosporine</title>
          <description>Cyclosporine (CsA) microemulsion at a starting dose of 8 to 10 milligram per kilogram per day (mg/kg/day) orally twice daily in 2 equal doses for 12 months. Dosages were adjusted according to trough whole blood level and standard institutional practice. Participants also received mycophenolate mofetil tablet 1 gram orally twice daily (up to 1.5 gram orally twice daily in Black participants) for 12 months.</description>
        </group>
        <group group_id="P2">
          <title>CP-690,550 15 mg for Months 1 to 6</title>
          <description>CP-690,550 15 milligram (mg) tablet orally twice daily for Month 1 to 6, then 10 mg tablet orally twice daily for Month 7 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
        </group>
        <group group_id="P3">
          <title>CP-690,550 15 mg for Months 1 to 3</title>
          <description>CP-690,550 15 mg tablet orally twice daily for Month 1 to 3, then 10 mg tablet orally twice daily for Month 4 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="106"/>
                <participants group_id="P3" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="52"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized, Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cyclosporine</title>
          <description>Cyclosporine (CsA) microemulsion at a starting dose of 8 to 10 milligram per kilogram per day (mg/kg/day) orally twice daily in 2 equal doses for 12 months. Dosages were adjusted according to trough whole blood level and standard institutional practice. Participants also received mycophenolate mofetil tablet 1 gram orally twice daily (up to 1.5 gram orally twice daily in Black participants) for 12 months.</description>
        </group>
        <group group_id="B2">
          <title>CP-690,550 15 mg for Months 1 to 6</title>
          <description>CP-690,550 15 milligram (mg) tablet orally twice daily for Month 1 to 6, then 10 mg tablet orally twice daily for Month 7 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
        </group>
        <group group_id="B3">
          <title>CP-690,550 15 mg for Months 1 to 3</title>
          <description>CP-690,550 15 mg tablet orally twice daily for Month 1 to 3, then 10 mg tablet orally twice daily for Month 4 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="109"/>
            <count group_id="B2" value="106"/>
            <count group_id="B3" value="107"/>
            <count group_id="B4" value="322"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 to 44 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 to 64 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater Than or Equal to (&gt;=) 65 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With First Clinical Biopsy Proven Acute Rejection (BPAR) Episode 6 Months Post-Transplant</title>
        <description>Clinical BPAR was a BPAR (category acute rejection as interpreted by the central blinded pathologist according to the Banff 97 working classification) associated with an increase in serum creatinine of &gt;= 0.3 milligram per deciliter (mg/dL) and &gt;=20 percent (%) from pre-rejection baseline. The increase in serum creatinine was assessed based on the comparison of baseline and the highest serum creatinine recorded within 24 hours (hrs) of the time of biopsy.</description>
        <time_frame>Baseline up to Month 6</time_frame>
        <population>Full analysis set (FAS) with last dosing risk set: all randomized participants who received at least 1 dose of study medication, including events occurring up to 7 days after last dose. Here, N (Number of Participants Analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA) microemulsion at a starting dose of 8 to 10 milligram per kilogram per day (mg/kg/day) orally twice daily in 2 equal doses for 12 months. Dosages were adjusted according to trough whole blood level and standard institutional practice. Participants also received mycophenolate mofetil tablet 1 gram orally twice daily (up to 1.5 gram orally twice daily in Black participants) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg for Months 1 to 6</title>
            <description>CP-690,550 15 milligram (mg) tablet orally twice daily for Month 1 to 6, then 10 mg tablet orally twice daily for Month 7 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 15 mg for Months 1 to 3</title>
            <description>CP-690,550 15 mg tablet orally twice daily for Month 1 to 3, then 10 mg tablet orally twice daily for Month 4 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Clinical Biopsy Proven Acute Rejection (BPAR) Episode 6 Months Post-Transplant</title>
          <description>Clinical BPAR was a BPAR (category acute rejection as interpreted by the central blinded pathologist according to the Banff 97 working classification) associated with an increase in serum creatinine of &gt;= 0.3 milligram per deciliter (mg/dL) and &gt;=20 percent (%) from pre-rejection baseline. The increase in serum creatinine was assessed based on the comparison of baseline and the highest serum creatinine recorded within 24 hours (hrs) of the time of biopsy.</description>
          <population>Full analysis set (FAS) with last dosing risk set: all randomized participants who received at least 1 dose of study medication, including events occurring up to 7 days after last dose. Here, N (Number of Participants Analyzed) signifies participants evaluable for this measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Glomerular Filtration Rate (GFR) at Month 12</title>
        <description>GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using iohexol serum clearance. For determination of iohexol serum clearance, iohexol was administered as an intravenous bolus over 5 minutes immediately after morning dosing of CP-690,550 or CsA on day of GFR evaluation. A normal GFR is greater than (&gt;) 90 milliliter per minute (mL/min), although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR less than (&lt;) 15 mL/min indicated kidney failure.</description>
        <time_frame>2, 3, 4, and 5 hrs post iohexol intravenous bolus at Month 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study medication. Here, N (Number of Participants Analyzed) includes only participants with evaluable data for this measure at Month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA) microemulsion at a starting dose of 8 to 10 milligram per kilogram per day (mg/kg/day) orally twice daily in 2 equal doses for 12 months. Dosages were adjusted according to trough whole blood level and standard institutional practice. Participants also received mycophenolate mofetil tablet 1 gram orally twice daily (up to 1.5 gram orally twice daily in Black participants) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg for Months 1 to 6</title>
            <description>CP-690,550 15 milligram (mg) tablet orally twice daily for Month 1 to 6, then 10 mg tablet orally twice daily for Month 7 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 15 mg for Months 1 to 3</title>
            <description>CP-690,550 15 mg tablet orally twice daily for Month 1 to 3, then 10 mg tablet orally twice daily for Month 4 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Glomerular Filtration Rate (GFR) at Month 12</title>
          <description>GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using iohexol serum clearance. For determination of iohexol serum clearance, iohexol was administered as an intravenous bolus over 5 minutes immediately after morning dosing of CP-690,550 or CsA on day of GFR evaluation. A normal GFR is greater than (&gt;) 90 milliliter per minute (mL/min), although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR less than (&lt;) 15 mL/min indicated kidney failure.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study medication. Here, N (Number of Participants Analyzed) includes only participants with evaluable data for this measure at Month 12.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.14" spread="19.12"/>
                    <measurement group_id="O2" value="65.05" spread="18.81"/>
                    <measurement group_id="O3" value="65.37" spread="20.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glomerular Filtration Rate (GFR) at Month 6</title>
        <description>GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using iohexol serum clearance. For determination of iohexol serum clearance, iohexol was administered as an intravenous bolus over 5 minutes immediately after morning dosing of CP-690,550 or CsA on day of GFR evaluation. A normal GFR is &gt;90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR &lt;15 mL/min indicated kidney failure.</description>
        <time_frame>2, 3, 4, and 5 hrs post iohexol intravenous bolus at Month 6</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study medication. Here, N (Number of Participants Analyzed) includes only participants with evaluable data for this measure at Month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA) microemulsion at a starting dose of 8 to 10 milligram per kilogram per day (mg/kg/day) orally twice daily in 2 equal doses for 12 months. Dosages were adjusted according to trough whole blood level and standard institutional practice. Participants also received mycophenolate mofetil tablet 1 gram orally twice daily (up to 1.5 gram orally twice daily in Black participants) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg for Months 1 to 6</title>
            <description>CP-690,550 15 milligram (mg) tablet orally twice daily for Month 1 to 6, then 10 mg tablet orally twice daily for Month 7 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 15 mg for Months 1 to 3</title>
            <description>CP-690,550 15 mg tablet orally twice daily for Month 1 to 3, then 10 mg tablet orally twice daily for Month 4 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Glomerular Filtration Rate (GFR) at Month 6</title>
          <description>GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using iohexol serum clearance. For determination of iohexol serum clearance, iohexol was administered as an intravenous bolus over 5 minutes immediately after morning dosing of CP-690,550 or CsA on day of GFR evaluation. A normal GFR is &gt;90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR &lt;15 mL/min indicated kidney failure.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study medication. Here, N (Number of Participants Analyzed) includes only participants with evaluable data for this measure at Month 6.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.29" spread="18.52"/>
                    <measurement group_id="O2" value="67.54" spread="21.86"/>
                    <measurement group_id="O3" value="73.93" spread="23.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Progression of Chronic Allograft Lesions at Month 12</title>
        <description>Progression of chronic allograft lesions was defined as an increase in the Banff chronicity score (Banff-CS) in biopsy from the implantation (baseline) biopsy in a given participant. Banff-CS was the sum of the Banff scores for the 4 chronic basic lesions (allograft glomerulopathy [cg] + interstitial fibrosis [ci] + tubular atrophy [ct] + vascular intimal thickening [cv]).The Banff-CS ranged from 0-12, higher score indicated greater lesions and Month 12 Banff-CS greater than the implantation biopsy score indicated progression of lesions.</description>
        <time_frame>Month 12</time_frame>
        <population>Per protocol (PP) population: all randomized participants who received at least 1 dose of study treatment; excluding participants who had a protocol deviation thought to affect the analyses. Here, N (Number of Participants Analyzed) includes only participants with evaluable data for this measure at both baseline and Month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA) microemulsion at a starting dose of 8 to 10 milligram per kilogram per day (mg/kg/day) orally twice daily in 2 equal doses for 12 months. Dosages were adjusted according to trough whole blood level and standard institutional practice. Participants also received mycophenolate mofetil tablet 1 gram orally twice daily (up to 1.5 gram orally twice daily in Black participants) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg for Months 1 to 6</title>
            <description>CP-690,550 15 milligram (mg) tablet orally twice daily for Month 1 to 6, then 10 mg tablet orally twice daily for Month 7 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 15 mg for Months 1 to 3</title>
            <description>CP-690,550 15 mg tablet orally twice daily for Month 1 to 3, then 10 mg tablet orally twice daily for Month 4 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Progression of Chronic Allograft Lesions at Month 12</title>
          <description>Progression of chronic allograft lesions was defined as an increase in the Banff chronicity score (Banff-CS) in biopsy from the implantation (baseline) biopsy in a given participant. Banff-CS was the sum of the Banff scores for the 4 chronic basic lesions (allograft glomerulopathy [cg] + interstitial fibrosis [ci] + tubular atrophy [ct] + vascular intimal thickening [cv]).The Banff-CS ranged from 0-12, higher score indicated greater lesions and Month 12 Banff-CS greater than the implantation biopsy score indicated progression of lesions.</description>
          <population>Per protocol (PP) population: all randomized participants who received at least 1 dose of study treatment; excluding participants who had a protocol deviation thought to affect the analyses. Here, N (Number of Participants Analyzed) includes only participants with evaluable data for this measure at both baseline and Month 12.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Clinical Biopsy Proven Acute Rejection (BPAR) 12 Months Post Transplant</title>
        <description>Clinical BPAR was a BPAR (category acute rejection as interpreted by the central blinded pathologist according to the Banff 97 working classification) associated with an increase in serum creatinine of &gt;= 0.3 mg/dL and &gt;=20% from pre-rejection baseline. The increase in serum creatinine was assessed based on the comparison of baseline and the highest serum creatinine recorded within 24 hrs of the time of biopsy.</description>
        <time_frame>Baseline up to Month 12</time_frame>
        <population>FAS with last dosing risk set: all randomized participants who received at least 1 dose of study medication, including events occurring up to 7 days after last dose. Here, N (Number of Participants Analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA) microemulsion at a starting dose of 8 to 10 milligram per kilogram per day (mg/kg/day) orally twice daily in 2 equal doses for 12 months. Dosages were adjusted according to trough whole blood level and standard institutional practice. Participants also received mycophenolate mofetil tablet 1 gram orally twice daily (up to 1.5 gram orally twice daily in Black participants) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg for Months 1 to 6</title>
            <description>CP-690,550 15 milligram (mg) tablet orally twice daily for Month 1 to 6, then 10 mg tablet orally twice daily for Month 7 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 15 mg for Months 1 to 3</title>
            <description>CP-690,550 15 mg tablet orally twice daily for Month 1 to 3, then 10 mg tablet orally twice daily for Month 4 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Clinical Biopsy Proven Acute Rejection (BPAR) 12 Months Post Transplant</title>
          <description>Clinical BPAR was a BPAR (category acute rejection as interpreted by the central blinded pathologist according to the Banff 97 working classification) associated with an increase in serum creatinine of &gt;= 0.3 mg/dL and &gt;=20% from pre-rejection baseline. The increase in serum creatinine was assessed based on the comparison of baseline and the highest serum creatinine recorded within 24 hrs of the time of biopsy.</description>
          <population>FAS with last dosing risk set: all randomized participants who received at least 1 dose of study medication, including events occurring up to 7 days after last dose. Here, N (Number of Participants Analyzed) signifies participants evaluable for this measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treated Clinical Acute Rejection</title>
        <description>Treated clinical acute rejection was defined as an acute rejection episode that was diagnosed based on local biopsy readout and received anti-rejection treatment.</description>
        <time_frame>Month 6, 12</time_frame>
        <population>FAS with last dosing risk set: all randomized participants who received at least 1 dose of study medication, including events occurring up to 7 days after last dose. Here, N (Number of Participants Analyzed): participants evaluable for this measure; and n: participants who remained at risk at given time point for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA) microemulsion at a starting dose of 8 to 10 milligram per kilogram per day (mg/kg/day) orally twice daily in 2 equal doses for 12 months. Dosages were adjusted according to trough whole blood level and standard institutional practice. Participants also received mycophenolate mofetil tablet 1 gram orally twice daily (up to 1.5 gram orally twice daily in Black participants) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg for Months 1 to 6</title>
            <description>CP-690,550 15 milligram (mg) tablet orally twice daily for Month 1 to 6, then 10 mg tablet orally twice daily for Month 7 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 15 mg for Months 1 to 3</title>
            <description>CP-690,550 15 mg tablet orally twice daily for Month 1 to 3, then 10 mg tablet orally twice daily for Month 4 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treated Clinical Acute Rejection</title>
          <description>Treated clinical acute rejection was defined as an acute rejection episode that was diagnosed based on local biopsy readout and received anti-rejection treatment.</description>
          <population>FAS with last dosing risk set: all randomized participants who received at least 1 dose of study medication, including events occurring up to 7 days after last dose. Here, N (Number of Participants Analyzed): participants evaluable for this measure; and n: participants who remained at risk at given time point for each group, respectively.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 (n=95,86,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=92,76,69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Combined Banff Rejection Categories (Categories 2, 3, and 4)</title>
        <description>Banff 97: standard classification for scoring and classifying rejection of kidney transplant biopsies in 6 diagnostic categories: normal, antibody-mediated rejection, borderline changes: suspicious for acute cellular rejection, acute/active cellular rejection, chronic/sclerosing allograft nephropathy, and other. Combined Banff rejection calculated from categories of antibody-mediated rejection (Category 2) plus borderline changes (Category 3) plus acute rejection (Category 4), as interpreted by the central pathologist.</description>
        <time_frame>Month 6, 12</time_frame>
        <population>FAS with last dosing risk set: all randomized participants who received at least 1 dose of study medication, including events occurring up to 7 days after last dose. Here, N (Number of Participants Analyzed): participants evaluable for this measure; and n: participants who were evaluable at given time point for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA) microemulsion at a starting dose of 8 to 10 milligram per kilogram per day (mg/kg/day) orally twice daily in 2 equal doses for 12 months. Dosages were adjusted according to trough whole blood level and standard institutional practice. Participants also received mycophenolate mofetil tablet 1 gram orally twice daily (up to 1.5 gram orally twice daily in Black participants) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg for Months 1 to 6</title>
            <description>CP-690,550 15 milligram (mg) tablet orally twice daily for Month 1 to 6, then 10 mg tablet orally twice daily for Month 7 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 15 mg for Months 1 to 3</title>
            <description>CP-690,550 15 mg tablet orally twice daily for Month 1 to 3, then 10 mg tablet orally twice daily for Month 4 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Combined Banff Rejection Categories (Categories 2, 3, and 4)</title>
          <description>Banff 97: standard classification for scoring and classifying rejection of kidney transplant biopsies in 6 diagnostic categories: normal, antibody-mediated rejection, borderline changes: suspicious for acute cellular rejection, acute/active cellular rejection, chronic/sclerosing allograft nephropathy, and other. Combined Banff rejection calculated from categories of antibody-mediated rejection (Category 2) plus borderline changes (Category 3) plus acute rejection (Category 4), as interpreted by the central pathologist.</description>
          <population>FAS with last dosing risk set: all randomized participants who received at least 1 dose of study medication, including events occurring up to 7 days after last dose. Here, N (Number of Participants Analyzed): participants evaluable for this measure; and n: participants who were evaluable at given time point for each group, respectively.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 (n=100,83,83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=96,74,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Graft Loss</title>
        <description>Graft loss was defined as graft nephrectomy, participant death, re-transplantation, or return to dialysis for &gt;=6 consecutive weeks.</description>
        <time_frame>Month 6, 12</time_frame>
        <population>FAS with last dosing risk set: all randomized participants who received at least 1 dose of study medication, including events occurring up to 7 days after last dose. Here, N (Number of Participants Analyzed): participants evaluable for this measure; and n: participants who remained at risk at given time point for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA) microemulsion at a starting dose of 8 to 10 milligram per kilogram per day (mg/kg/day) orally twice daily in 2 equal doses for 12 months. Dosages were adjusted according to trough whole blood level and standard institutional practice. Participants also received mycophenolate mofetil tablet 1 gram orally twice daily (up to 1.5 gram orally twice daily in Black participants) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg for Months 1 to 6</title>
            <description>CP-690,550 15 milligram (mg) tablet orally twice daily for Month 1 to 6, then 10 mg tablet orally twice daily for Month 7 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 15 mg for Months 1 to 3</title>
            <description>CP-690,550 15 mg tablet orally twice daily for Month 1 to 3, then 10 mg tablet orally twice daily for Month 4 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Graft Loss</title>
          <description>Graft loss was defined as graft nephrectomy, participant death, re-transplantation, or return to dialysis for &gt;=6 consecutive weeks.</description>
          <population>FAS with last dosing risk set: all randomized participants who received at least 1 dose of study medication, including events occurring up to 7 days after last dose. Here, N (Number of Participants Analyzed): participants evaluable for this measure; and n: participants who remained at risk at given time point for each group, respectively.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 (n=85,68,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=79,56,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Efficacy Failure</title>
        <description>Efficacy failure was the first occurrence of clinical BPAR diagnosed by the central pathologist or graft loss including participant death.</description>
        <time_frame>Month 6, 12</time_frame>
        <population>FAS with last dosing risk set: all randomized participants who received at least 1 dose of study medication, including events occurring up to 7 days after last dose. Here, N (Number of Participants Analyzed): participants evaluable for this measure; and n: participants who remained at risk at given time point for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA) microemulsion at a starting dose of 8 to 10 milligram per kilogram per day (mg/kg/day) orally twice daily in 2 equal doses for 12 months. Dosages were adjusted according to trough whole blood level and standard institutional practice. Participants also received mycophenolate mofetil tablet 1 gram orally twice daily (up to 1.5 gram orally twice daily in Black participants) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg for Months 1 to 6</title>
            <description>CP-690,550 15 milligram (mg) tablet orally twice daily for Month 1 to 6, then 10 mg tablet orally twice daily for Month 7 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 15 mg for Months 1 to 3</title>
            <description>CP-690,550 15 mg tablet orally twice daily for Month 1 to 3, then 10 mg tablet orally twice daily for Month 4 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Efficacy Failure</title>
          <description>Efficacy failure was the first occurrence of clinical BPAR diagnosed by the central pathologist or graft loss including participant death.</description>
          <population>FAS with last dosing risk set: all randomized participants who received at least 1 dose of study medication, including events occurring up to 7 days after last dose. Here, N (Number of Participants Analyzed): participants evaluable for this measure; and n: participants who remained at risk at given time point for each group, respectively.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 (n=98,84,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=94,74,67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died</title>
        <time_frame>Month 6, 12</time_frame>
        <population>FAS with last dosing risk set: all randomized participants who received at least 1 dose of study medication, including events occurring up to 7 days after last dose. Here, N (Number of Participants Analyzed): participants evaluable for this measure; and n: participants who remained at risk at given time point for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA) microemulsion at a starting dose of 8 to 10 milligram per kilogram per day (mg/kg/day) orally twice daily in 2 equal doses for 12 months. Dosages were adjusted according to trough whole blood level and standard institutional practice. Participants also received mycophenolate mofetil tablet 1 gram orally twice daily (up to 1.5 gram orally twice daily in Black participants) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg for Months 1 to 6</title>
            <description>CP-690,550 15 milligram (mg) tablet orally twice daily for Month 1 to 6, then 10 mg tablet orally twice daily for Month 7 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 15 mg for Months 1 to 3</title>
            <description>CP-690,550 15 mg tablet orally twice daily for Month 1 to 3, then 10 mg tablet orally twice daily for Month 4 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died</title>
          <population>FAS with last dosing risk set: all randomized participants who received at least 1 dose of study medication, including events occurring up to 7 days after last dose. Here, N (Number of Participants Analyzed): participants evaluable for this measure; and n: participants who remained at risk at given time point for each group, respectively.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 (n=86,69,69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=80,57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lymphocyte Subset</title>
        <description>The absolute cell counts of cluster of differentiation 3 (CD3): T-lymphocytes, cluster of differentiation 19 (CD19): B-lymphocytes, and cluster of differentiation 56 (CD56): assumed natural killer cells, were determined using flow cytometry.</description>
        <time_frame>Month 1, 3, 6, 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study medication. Here, N (Number of Participants Analyzed) signifies participants evaluable for this measure; and 'n' signifies those participants who were evaluable at given time point for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA) microemulsion at a starting dose of 8 to 10 milligram per kilogram per day (mg/kg/day) orally twice daily in 2 equal doses for 12 months. Dosages were adjusted according to trough whole blood level and standard institutional practice. Participants also received mycophenolate mofetil tablet 1 gram orally twice daily (up to 1.5 gram orally twice daily in Black participants) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg for Months 1 to 6</title>
            <description>CP-690,550 15 milligram (mg) tablet orally twice daily for Month 1 to 6, then 10 mg tablet orally twice daily for Month 7 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 15 mg for Months 1 to 3</title>
            <description>CP-690,550 15 mg tablet orally twice daily for Month 1 to 3, then 10 mg tablet orally twice daily for Month 4 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Lymphocyte Subset</title>
          <description>The absolute cell counts of cluster of differentiation 3 (CD3): T-lymphocytes, cluster of differentiation 19 (CD19): B-lymphocytes, and cluster of differentiation 56 (CD56): assumed natural killer cells, were determined using flow cytometry.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study medication. Here, N (Number of Participants Analyzed) signifies participants evaluable for this measure; and 'n' signifies those participants who were evaluable at given time point for each group, respectively.</population>
          <units>cells per microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD3: Month 1 (n=60,54,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1555.0" spread="925.45"/>
                    <measurement group_id="O2" value="1256.7" spread="708.47"/>
                    <measurement group_id="O3" value="1327.2" spread="627.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3: Month 3 (n=59,44,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1273.2" spread="742.82"/>
                    <measurement group_id="O2" value="894.20" spread="527.87"/>
                    <measurement group_id="O3" value="1007.1" spread="447.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3: Month 6 (n=47,34,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1267.9" spread="693.20"/>
                    <measurement group_id="O2" value="811.74" spread="379.16"/>
                    <measurement group_id="O3" value="970.39" spread="410.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD3: Month 12 (n=45,29,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1352.5" spread="647.60"/>
                    <measurement group_id="O2" value="796.76" spread="368.51"/>
                    <measurement group_id="O3" value="956.04" spread="522.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19: Month 1 (n=60,54,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280.58" spread="220.96"/>
                    <measurement group_id="O2" value="409.39" spread="339.45"/>
                    <measurement group_id="O3" value="416.70" spread="304.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19: Month 3 (n=58,44,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.47" spread="208.07"/>
                    <measurement group_id="O2" value="189.41" spread="190.23"/>
                    <measurement group_id="O3" value="185.68" spread="139.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19: Month 6 (n=47,34,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.26" spread="164.65"/>
                    <measurement group_id="O2" value="151.03" spread="129.52"/>
                    <measurement group_id="O3" value="173.10" spread="136.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD19: Month 12 (n=45,29,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.18" spread="117.14"/>
                    <measurement group_id="O2" value="180.03" spread="235.85"/>
                    <measurement group_id="O3" value="181.46" spread="141.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56: Month 1 (n=60,54,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.47" spread="93.95"/>
                    <measurement group_id="O2" value="116.65" spread="110.62"/>
                    <measurement group_id="O3" value="112.23" spread="110.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56: Month 3 (n=58,44,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.14" spread="86.42"/>
                    <measurement group_id="O2" value="86.86" spread="97.80"/>
                    <measurement group_id="O3" value="65.38" spread="38.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56: Month 6 (n=47,34,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170.23" spread="123.27"/>
                    <measurement group_id="O2" value="68.06" spread="63.85"/>
                    <measurement group_id="O3" value="65.00" spread="48.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56: Month 12 (n=45,29,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.91" spread="122.80"/>
                    <measurement group_id="O2" value="96.00" spread="100.85"/>
                    <measurement group_id="O3" value="77.23" spread="57.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population Pharmacokinetics (PK)</title>
        <description>Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.</description>
        <time_frame>Pre-dose-2(P-2), Pre-dose(P), 0.5,1,2 hr post-dose(PD) on Day14, Month(M) 3; P,1,2 hr PD on M1; P, 0.5, 2, 4 hr PD on M6; P-2, P, 0.5 hr PD on M9, M12 as per randomization in CP-690,550 treated; P on M3 and P, 2, 4 hr PD on M6 in CsA treated participants</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glomerular Filtration Rate (GFR) by The Nankivell Equation</title>
        <description>GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated was estimated by creatinine clearance (CLcr) using Nankivell equation. CLcr by Nankivell equation= (6.7 per serum creatinine) plus (0.25*body weight) minus (0.5*serum urea) minus (100 per height square) plus (35 for male/25 for female). A normal GFR is &gt;90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR &lt;15 mL/min indicated kidney failure.</description>
        <time_frame>Month 1, 3, 6, 9, 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study medication. Here, N (Number of Participants Analyzed) signifies participants evaluable for this measure. Missing data were imputed using Last Observation Carried Forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA) microemulsion at a starting dose of 8 to 10 milligram per kilogram per day (mg/kg/day) orally twice daily in 2 equal doses for 12 months. Dosages were adjusted according to trough whole blood level and standard institutional practice. Participants also received mycophenolate mofetil tablet 1 gram orally twice daily (up to 1.5 gram orally twice daily in Black participants) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg for Months 1 to 6</title>
            <description>CP-690,550 15 milligram (mg) tablet orally twice daily for Month 1 to 6, then 10 mg tablet orally twice daily for Month 7 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 15 mg for Months 1 to 3</title>
            <description>CP-690,550 15 mg tablet orally twice daily for Month 1 to 3, then 10 mg tablet orally twice daily for Month 4 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Glomerular Filtration Rate (GFR) by The Nankivell Equation</title>
          <description>GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated was estimated by creatinine clearance (CLcr) using Nankivell equation. CLcr by Nankivell equation= (6.7 per serum creatinine) plus (0.25*body weight) minus (0.5*serum urea) minus (100 per height square) plus (35 for male/25 for female). A normal GFR is &gt;90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR &lt;15 mL/min indicated kidney failure.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study medication. Here, N (Number of Participants Analyzed) signifies participants evaluable for this measure. Missing data were imputed using Last Observation Carried Forward (LOCF).</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.85" spread="19.73"/>
                    <measurement group_id="O2" value="71.53" spread="17.72"/>
                    <measurement group_id="O3" value="73.66" spread="16.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.80" spread="17.88"/>
                    <measurement group_id="O2" value="73.58" spread="18.46"/>
                    <measurement group_id="O3" value="72.91" spread="16.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.75" spread="18.75"/>
                    <measurement group_id="O2" value="73.23" spread="18.26"/>
                    <measurement group_id="O3" value="74.49" spread="16.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.85" spread="20.33"/>
                    <measurement group_id="O2" value="74.29" spread="18.23"/>
                    <measurement group_id="O3" value="74.22" spread="16.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.88" spread="21.87"/>
                    <measurement group_id="O2" value="75.58" spread="18.54"/>
                    <measurement group_id="O3" value="75.41" spread="17.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glomerular Filtration Rate (GFR) by The Cockcroft-Gault Equation</title>
        <description>GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated using Cockcroft-Gault equation. GFR by Cockcroft-Gault equation= body weight*(140 minus age in years) divided by (72*serum creatinine). For females value obtained was multiplied by 0.85. A normal GFR is &gt;90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR &lt;15 mL/min indicated kidney failure.</description>
        <time_frame>Month 1, 3, 6, 9, 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study medication. Here, N (Number of Participants Analyzed) signifies participants evaluable for this measure. Missing data were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA) microemulsion at a starting dose of 8 to 10 milligram per kilogram per day (mg/kg/day) orally twice daily in 2 equal doses for 12 months. Dosages were adjusted according to trough whole blood level and standard institutional practice. Participants also received mycophenolate mofetil tablet 1 gram orally twice daily (up to 1.5 gram orally twice daily in Black participants) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg for Months 1 to 6</title>
            <description>CP-690,550 15 milligram (mg) tablet orally twice daily for Month 1 to 6, then 10 mg tablet orally twice daily for Month 7 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 15 mg for Months 1 to 3</title>
            <description>CP-690,550 15 mg tablet orally twice daily for Month 1 to 3, then 10 mg tablet orally twice daily for Month 4 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Glomerular Filtration Rate (GFR) by The Cockcroft-Gault Equation</title>
          <description>GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated using Cockcroft-Gault equation. GFR by Cockcroft-Gault equation= body weight*(140 minus age in years) divided by (72*serum creatinine). For females value obtained was multiplied by 0.85. A normal GFR is &gt;90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR &lt;15 mL/min indicated kidney failure.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study medication. Here, N (Number of Participants Analyzed) signifies participants evaluable for this measure. Missing data were imputed using LOCF.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.23" spread="23.84"/>
                    <measurement group_id="O2" value="71.12" spread="23.31"/>
                    <measurement group_id="O3" value="73.55" spread="20.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.08" spread="23.19"/>
                    <measurement group_id="O2" value="74.41" spread="25.76"/>
                    <measurement group_id="O3" value="74.16" spread="22.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.21" spread="23.66"/>
                    <measurement group_id="O2" value="74.71" spread="25.87"/>
                    <measurement group_id="O3" value="76.30" spread="23.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.05" spread="25.15"/>
                    <measurement group_id="O2" value="76.41" spread="25.62"/>
                    <measurement group_id="O3" value="76.40" spread="24.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.67" spread="25.64"/>
                    <measurement group_id="O2" value="78.41" spread="27.62"/>
                    <measurement group_id="O3" value="78.09" spread="24.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glomerular Filtration Rate (GFR) by The Modification of Diet in Renal Disease (MDRD) Equation</title>
        <description>GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using MDRD equation. GFR by MDRD equation = 170 * (serum creatinine)^(-0.999) * (age in years)^(-0.176) * (0.762 if female) * (1.18 if black) * (blood urea nitrogen concentration)^(-0.170) * (serum albumin concentration)^(0.318).A normal GFR is &gt;90 mL/min/1.73 square meter (m^2), although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR &lt;15 mL/min/1.73 m^2 indicated kidney failure.</description>
        <time_frame>Month 1, 3, 6, 9, 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study medication. Here, N (Number of Participants Analyzed) signifies participants evaluable for this measure. Missing data were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA) microemulsion at a starting dose of 8 to 10 milligram per kilogram per day (mg/kg/day) orally twice daily in 2 equal doses for 12 months. Dosages were adjusted according to trough whole blood level and standard institutional practice. Participants also received mycophenolate mofetil tablet 1 gram orally twice daily (up to 1.5 gram orally twice daily in Black participants) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg for Months 1 to 6</title>
            <description>CP-690,550 15 milligram (mg) tablet orally twice daily for Month 1 to 6, then 10 mg tablet orally twice daily for Month 7 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 15 mg for Months 1 to 3</title>
            <description>CP-690,550 15 mg tablet orally twice daily for Month 1 to 3, then 10 mg tablet orally twice daily for Month 4 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Glomerular Filtration Rate (GFR) by The Modification of Diet in Renal Disease (MDRD) Equation</title>
          <description>GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using MDRD equation. GFR by MDRD equation = 170 * (serum creatinine)^(-0.999) * (age in years)^(-0.176) * (0.762 if female) * (1.18 if black) * (blood urea nitrogen concentration)^(-0.170) * (serum albumin concentration)^(0.318).A normal GFR is &gt;90 mL/min/1.73 square meter (m^2), although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR &lt;15 mL/min/1.73 m^2 indicated kidney failure.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study medication. Here, N (Number of Participants Analyzed) signifies participants evaluable for this measure. Missing data were imputed using LOCF.</population>
          <units>mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.89" spread="20.05"/>
                    <measurement group_id="O2" value="59.93" spread="17.54"/>
                    <measurement group_id="O3" value="63.61" spread="21.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.55" spread="18.83"/>
                    <measurement group_id="O2" value="62.20" spread="17.16"/>
                    <measurement group_id="O3" value="62.81" spread="20.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.16" spread="19.21"/>
                    <measurement group_id="O2" value="61.84" spread="17.71"/>
                    <measurement group_id="O3" value="64.04" spread="19.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.11" spread="20.45"/>
                    <measurement group_id="O2" value="62.98" spread="17.50"/>
                    <measurement group_id="O3" value="63.61" spread="18.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.94" spread="21.36"/>
                    <measurement group_id="O2" value="64.25" spread="18.28"/>
                    <measurement group_id="O3" value="64.59" spread="20.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glomerular Filtration Rate (GFR) by The Abbreviated Modification of Diet in Renal Disease (MDRD) Equation</title>
        <description>GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated using abbreviated MDRD equation. GFR by abbreviated MDRD equation= 186 * (serum creatinine)^(-1.154) * (age in years)^(-0.203) * (0.742 if female) * (1.210 if black). A normal GFR is &gt;90 mL/min/1.73 m^2, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR &lt;15 mL/min/1.73 m^2 indicated kidney failure.</description>
        <time_frame>Month 1, 3, 6, 9, 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study medication. Here, N (Number of Participants Analyzed) signifies participants evaluable for this measure. Missing data were imputed using LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA) microemulsion at a starting dose of 8 to 10 milligram per kilogram per day (mg/kg/day) orally twice daily in 2 equal doses for 12 months. Dosages were adjusted according to trough whole blood level and standard institutional practice. Participants also received mycophenolate mofetil tablet 1 gram orally twice daily (up to 1.5 gram orally twice daily in Black participants) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg for Months 1 to 6</title>
            <description>CP-690,550 15 milligram (mg) tablet orally twice daily for Month 1 to 6, then 10 mg tablet orally twice daily for Month 7 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 15 mg for Months 1 to 3</title>
            <description>CP-690,550 15 mg tablet orally twice daily for Month 1 to 3, then 10 mg tablet orally twice daily for Month 4 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Glomerular Filtration Rate (GFR) by The Abbreviated Modification of Diet in Renal Disease (MDRD) Equation</title>
          <description>GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated using abbreviated MDRD equation. GFR by abbreviated MDRD equation= 186 * (serum creatinine)^(-1.154) * (age in years)^(-0.203) * (0.742 if female) * (1.210 if black). A normal GFR is &gt;90 mL/min/1.73 m^2, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR &lt;15 mL/min/1.73 m^2 indicated kidney failure.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study medication. Here, N (Number of Participants Analyzed) signifies participants evaluable for this measure. Missing data were imputed using LOCF.</population>
          <units>mL/min per 1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.29" spread="21.96"/>
                    <measurement group_id="O2" value="61.49" spread="18.66"/>
                    <measurement group_id="O3" value="64.81" spread="21.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.36" spread="19.28"/>
                    <measurement group_id="O2" value="62.45" spread="18.39"/>
                    <measurement group_id="O3" value="62.27" spread="19.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.01" spread="20.22"/>
                    <measurement group_id="O2" value="61.49" spread="18.10"/>
                    <measurement group_id="O3" value="63.33" spread="19.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.39" spread="22.09"/>
                    <measurement group_id="O2" value="62.52" spread="17.86"/>
                    <measurement group_id="O3" value="62.76" spread="18.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.99" spread="24.15"/>
                    <measurement group_id="O2" value="63.88" spread="18.40"/>
                    <measurement group_id="O3" value="64.17" spread="19.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Infections</title>
        <description>Clinically significant infection was defined as the presence of documented infection confirmed by culture, biopsy, genomic, or serologic findings post-randomization and requiring hospitalization or parenteral anti-infective treatment, or otherwise deemed significant by the investigator.</description>
        <time_frame>Baseline up to Month 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA) microemulsion at a starting dose of 8 to 10 milligram per kilogram per day (mg/kg/day) orally twice daily in 2 equal doses for 12 months. Dosages were adjusted according to trough whole blood level and standard institutional practice. Participants also received mycophenolate mofetil tablet 1 gram orally twice daily (up to 1.5 gram orally twice daily in Black participants) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg for Months 1 to 6</title>
            <description>CP-690,550 15 milligram (mg) tablet orally twice daily for Month 1 to 6, then 10 mg tablet orally twice daily for Month 7 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 15 mg for Months 1 to 3</title>
            <description>CP-690,550 15 mg tablet orally twice daily for Month 1 to 3, then 10 mg tablet orally twice daily for Month 4 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Infections</title>
          <description>Clinically significant infection was defined as the presence of documented infection confirmed by culture, biopsy, genomic, or serologic findings post-randomization and requiring hospitalization or parenteral anti-infective treatment, or otherwise deemed significant by the investigator.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>36-Item Short-Form Health Survey (SF-36)</title>
        <description>SF-36: standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as physical and mental component scores. Total of 11 variables were analyzed (8 subscales,2 composite subscales and Question(Q) 2 how would you rate your health in general now?(range 1=better, 5=worst). The score for a section (except Q2) is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).</description>
        <time_frame>Baseline, Month 6, 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study medication. Here, N (Number of Participants Analyzed) signifies participants evaluable for this measure; and 'n' signifies those participants who were evaluable at given time point for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA) microemulsion at a starting dose of 8 to 10 milligram per kilogram per day (mg/kg/day) orally twice daily in 2 equal doses for 12 months. Dosages were adjusted according to trough whole blood level and standard institutional practice. Participants also received mycophenolate mofetil tablet 1 gram orally twice daily (up to 1.5 gram orally twice daily in Black participants) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg for Months 1 to 6</title>
            <description>CP-690,550 15 milligram (mg) tablet orally twice daily for Month 1 to 6, then 10 mg tablet orally twice daily for Month 7 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 15 mg for Months 1 to 3</title>
            <description>CP-690,550 15 mg tablet orally twice daily for Month 1 to 3, then 10 mg tablet orally twice daily for Month 4 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>36-Item Short-Form Health Survey (SF-36)</title>
          <description>SF-36: standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as physical and mental component scores. Total of 11 variables were analyzed (8 subscales,2 composite subscales and Question(Q) 2 how would you rate your health in general now?(range 1=better, 5=worst). The score for a section (except Q2) is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).</description>
          <population>FAS: all randomized participants who received at least 1 dose of study medication. Here, N (Number of Participants Analyzed) signifies participants evaluable for this measure; and 'n' signifies those participants who were evaluable at given time point for each group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Bodily Pain (n=79,68,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.89" spread="9.45"/>
                    <measurement group_id="O2" value="51.43" spread="10.56"/>
                    <measurement group_id="O3" value="49.56" spread="10.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: General Health (n=79,68,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.77" spread="9.28"/>
                    <measurement group_id="O2" value="42.46" spread="10.63"/>
                    <measurement group_id="O3" value="42.39" spread="9.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Mental Health (n=78,68,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.15" spread="9.13"/>
                    <measurement group_id="O2" value="44.85" spread="12.75"/>
                    <measurement group_id="O3" value="48.69" spread="11.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Physical Functioning (n=79,68,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.03" spread="10.03"/>
                    <measurement group_id="O2" value="44.46" spread="9.58"/>
                    <measurement group_id="O3" value="45.88" spread="9.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Role Emotional (n=79,68,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.19" spread="11.75"/>
                    <measurement group_id="O2" value="43.82" spread="13.80"/>
                    <measurement group_id="O3" value="43.79" spread="13.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Role Physical (n=79,68,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.26" spread="11.86"/>
                    <measurement group_id="O2" value="42.28" spread="12.56"/>
                    <measurement group_id="O3" value="42.51" spread="12.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Social Functioning (n=79,68,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.42" spread="8.98"/>
                    <measurement group_id="O2" value="41.14" spread="12.42"/>
                    <measurement group_id="O3" value="44.38" spread="11.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Vitality (n=78,68,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.77" spread="10.81"/>
                    <measurement group_id="O2" value="48.04" spread="12.38"/>
                    <measurement group_id="O3" value="50.29" spread="10.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Physical Component (n=78,68,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.85" spread="9.38"/>
                    <measurement group_id="O2" value="45.85" spread="8.35"/>
                    <measurement group_id="O3" value="45.05" spread="8.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Mental Component (n=78,68,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.41" spread="9.66"/>
                    <measurement group_id="O2" value="44.18" spread="13.27"/>
                    <measurement group_id="O3" value="47.13" spread="11.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Q2-Health in General Now (n=80,68,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.78" spread="0.62"/>
                    <measurement group_id="O2" value="2.57" spread="0.78"/>
                    <measurement group_id="O3" value="2.63" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Bodily Pain (n=78,63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.87" spread="9.55"/>
                    <measurement group_id="O2" value="49.76" spread="11.49"/>
                    <measurement group_id="O3" value="50.88" spread="10.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: General Health (n=78,63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.87" spread="9.00"/>
                    <measurement group_id="O2" value="46.70" spread="10.31"/>
                    <measurement group_id="O3" value="47.36" spread="9.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Mental Health (n=78,63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.47" spread="10.69"/>
                    <measurement group_id="O2" value="48.35" spread="12.48"/>
                    <measurement group_id="O3" value="48.81" spread="10.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Physical Functioning (n=77,63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.06" spread="9.96"/>
                    <measurement group_id="O2" value="45.74" spread="11.08"/>
                    <measurement group_id="O3" value="46.91" spread="10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Role Emotional (n=77,63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.06" spread="11.15"/>
                    <measurement group_id="O2" value="45.40" spread="11.82"/>
                    <measurement group_id="O3" value="46.77" spread="11.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Role Physical (n=77,63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.48" spread="10.44"/>
                    <measurement group_id="O2" value="43.11" spread="12.14"/>
                    <measurement group_id="O3" value="45.87" spread="10.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Social Functioning (n=78,63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.34" spread="8.64"/>
                    <measurement group_id="O2" value="45.14" spread="12.21"/>
                    <measurement group_id="O3" value="47.88" spread="10.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Vitality (n=78,63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.22" spread="9.70"/>
                    <measurement group_id="O2" value="52.13" spread="11.14"/>
                    <measurement group_id="O3" value="51.95" spread="10.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Physical Component (n=77,63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.93" spread="8.27"/>
                    <measurement group_id="O2" value="46.22" spread="10.76"/>
                    <measurement group_id="O3" value="47.82" spread="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Mental Component (n=77,63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.60" spread="9.43"/>
                    <measurement group_id="O2" value="48.30" spread="11.82"/>
                    <measurement group_id="O3" value="49.09" spread="10.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Q2-Health in General Now (n=78,63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.74" spread="0.73"/>
                    <measurement group_id="O2" value="2.65" spread="0.77"/>
                    <measurement group_id="O3" value="2.72" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: Bodily Pain (n=73,58,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.12" spread="9.23"/>
                    <measurement group_id="O2" value="51.07" spread="10.24"/>
                    <measurement group_id="O3" value="49.48" spread="10.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: General Health (n=73,57,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.94" spread="8.74"/>
                    <measurement group_id="O2" value="46.79" spread="8.71"/>
                    <measurement group_id="O3" value="44.71" spread="10.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: Mental Health (n=73,57,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.93" spread="9.24"/>
                    <measurement group_id="O2" value="49.43" spread="10.98"/>
                    <measurement group_id="O3" value="46.91" spread="10.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: Physical Functioning (n=73,58,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.19" spread="10.26"/>
                    <measurement group_id="O2" value="46.88" spread="10.16"/>
                    <measurement group_id="O3" value="46.99" spread="11.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: Role Emotional (n=71,57,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.13" spread="12.36"/>
                    <measurement group_id="O2" value="47.31" spread="9.15"/>
                    <measurement group_id="O3" value="46.21" spread="12.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: Role Physical (n=71,57,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.57" spread="9.68"/>
                    <measurement group_id="O2" value="44.19" spread="10.73"/>
                    <measurement group_id="O3" value="45.20" spread="11.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: Social Functioning (n=73,57,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.63" spread="8.41"/>
                    <measurement group_id="O2" value="46.87" spread="10.06"/>
                    <measurement group_id="O3" value="47.18" spread="10.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: Vitality (n=73,57,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.25" spread="8.31"/>
                    <measurement group_id="O2" value="51.45" spread="11.20"/>
                    <measurement group_id="O3" value="51.69" spread="10.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: Physical Component (n=71,57,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.98" spread="8.02"/>
                    <measurement group_id="O2" value="46.84" spread="8.80"/>
                    <measurement group_id="O3" value="47.03" spread="10.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: Mental Component (n=71,57,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.12" spread="9.34"/>
                    <measurement group_id="O2" value="49.47" spread="9.36"/>
                    <measurement group_id="O3" value="47.91" spread="12.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: Q2-Health in General Now (n=73,58,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" spread="0.62"/>
                    <measurement group_id="O2" value="2.69" spread="0.71"/>
                    <measurement group_id="O3" value="2.84" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>End-Stage Renal Disease Symptom Checklist Transplantation Module (ESRD-SCL)</title>
        <description>ESRD-SCL:43-item disease specific self-administered questionnaire. Participants rated questionAt the moment,how much do you suffer?for each item on 5 point scale,ranged (Ra) 0(not at all)to 4(extremely).Consisted of 6 subscales:cardiac and renal dysfunction;Ra 0-28,increased(In) growth of gum and hair;Ra 0-20,limited cognitive capacity;Ra 0-32,limited physical capacity;Ra 0 - 40,side effects (SEs) of corticosteroids;Ra 0-20,transplantation associated psychological distress(TAPD);Ra 0-32(higher scores=greater dysfunction for each subscale).Total score:0-172,higher scores=greater dysfunction.</description>
        <time_frame>Baseline, Month 6, 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study medication. Here, N (Number of Participants Analyzed) signifies participants evaluable for this measure; and 'n' signifies those participants who were evaluable at given time point for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA) microemulsion at a starting dose of 8 to 10 milligram per kilogram per day (mg/kg/day) orally twice daily in 2 equal doses for 12 months. Dosages were adjusted according to trough whole blood level and standard institutional practice. Participants also received mycophenolate mofetil tablet 1 gram orally twice daily (up to 1.5 gram orally twice daily in Black participants) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg for Months 1 to 6</title>
            <description>CP-690,550 15 milligram (mg) tablet orally twice daily for Month 1 to 6, then 10 mg tablet orally twice daily for Month 7 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 15 mg for Months 1 to 3</title>
            <description>CP-690,550 15 mg tablet orally twice daily for Month 1 to 3, then 10 mg tablet orally twice daily for Month 4 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>End-Stage Renal Disease Symptom Checklist Transplantation Module (ESRD-SCL)</title>
          <description>ESRD-SCL:43-item disease specific self-administered questionnaire. Participants rated questionAt the moment,how much do you suffer?for each item on 5 point scale,ranged (Ra) 0(not at all)to 4(extremely).Consisted of 6 subscales:cardiac and renal dysfunction;Ra 0-28,increased(In) growth of gum and hair;Ra 0-20,limited cognitive capacity;Ra 0-32,limited physical capacity;Ra 0 - 40,side effects (SEs) of corticosteroids;Ra 0-20,transplantation associated psychological distress(TAPD);Ra 0-32(higher scores=greater dysfunction for each subscale).Total score:0-172,higher scores=greater dysfunction.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study medication. Here, N (Number of Participants Analyzed) signifies participants evaluable for this measure; and 'n' signifies those participants who were evaluable at given time point for each group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline:Cardiac and Renal Dysfunction(n=76,61,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.55"/>
                    <measurement group_id="O2" value="0.70" spread="0.59"/>
                    <measurement group_id="O3" value="0.64" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: In Growth of Gum and Hair (n=76,61,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.36"/>
                    <measurement group_id="O2" value="0.16" spread="0.31"/>
                    <measurement group_id="O3" value="0.18" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Limited Cognitive Capacity (n=77,62,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.63"/>
                    <measurement group_id="O2" value="0.76" spread="0.74"/>
                    <measurement group_id="O3" value="0.64" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Limited Physical Capacity (n=76,61,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.59"/>
                    <measurement group_id="O2" value="0.79" spread="0.65"/>
                    <measurement group_id="O3" value="0.72" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: SEs of Corticosteroids (n=76,61,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.53"/>
                    <measurement group_id="O2" value="0.56" spread="0.64"/>
                    <measurement group_id="O3" value="0.48" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: TAPD (n=77,62,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="0.68"/>
                    <measurement group_id="O2" value="1.21" spread="0.82"/>
                    <measurement group_id="O3" value="1.16" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6:Cardiac and Renal Dysfunction(n=77,63,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="0.63"/>
                    <measurement group_id="O2" value="0.40" spread="0.50"/>
                    <measurement group_id="O3" value="0.50" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: In Growth of Gum and Hair (n=77,63,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.61"/>
                    <measurement group_id="O2" value="0.23" spread="0.47"/>
                    <measurement group_id="O3" value="0.24" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Limited Cognitive Capacity (n=77,64,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.68"/>
                    <measurement group_id="O2" value="0.70" spread="0.74"/>
                    <measurement group_id="O3" value="0.68" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Limited Physical Capacity (n=77,63,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="0.60"/>
                    <measurement group_id="O2" value="0.67" spread="0.61"/>
                    <measurement group_id="O3" value="0.62" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: SEs of Corticosteroids (n=77,63,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.70"/>
                    <measurement group_id="O2" value="0.54" spread="0.56"/>
                    <measurement group_id="O3" value="0.69" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: TAPD (n=77,64,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="0.60"/>
                    <measurement group_id="O2" value="0.78" spread="0.65"/>
                    <measurement group_id="O3" value="0.85" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12:Cardiac and Renal Dysfunction(n=70,57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.46"/>
                    <measurement group_id="O2" value="0.51" spread="0.48"/>
                    <measurement group_id="O3" value="0.49" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: In Growth of Gum and Hair (n=70,57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.52"/>
                    <measurement group_id="O2" value="0.19" spread="0.30"/>
                    <measurement group_id="O3" value="0.29" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: Limited Cognitive Capacity (n=71,58,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.60"/>
                    <measurement group_id="O2" value="0.79" spread="0.70"/>
                    <measurement group_id="O3" value="0.85" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: Limited Physical Capacity (n=70,57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.46"/>
                    <measurement group_id="O2" value="0.69" spread="0.50"/>
                    <measurement group_id="O3" value="0.73" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: SEs of Corticosteroids (n=70,56,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.48"/>
                    <measurement group_id="O2" value="0.56" spread="0.63"/>
                    <measurement group_id="O3" value="0.72" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: TAPD (n=71,57,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.53"/>
                    <measurement group_id="O2" value="0.90" spread="0.66"/>
                    <measurement group_id="O3" value="0.96" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Dyspepsia Assessment (SODA)</title>
        <description>SODA:17-item health scale, assessed participant-reported perceptions of dyspepsia;consists of 3 subscales:Pain Intensity (6-items to assess pain and intensity of abdominal [Ab] discomfort; Range (Ra):2-47, higher score= greater pain and Ab discomfort), Non-Pain Symptoms (7-items to assess severity and impact of non-pain symptoms:burping/belching,heartburn,bloating,flatulence,sour taste,nausea,and bad breath; Ra:7-35,higher scores = increased symptom severity and influence), and Satisfaction (4-items to assess degree of satisfaction with Ab discomfort; Ra:2-23,higher scores= more satisfaction).</description>
        <time_frame>Baseline, Month 6, 12</time_frame>
        <population>Data not analyzed since the SODA instrument was found irrelevant in the treated population.</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine</title>
            <description>Cyclosporine (CsA) microemulsion at a starting dose of 8 to 10 milligram per kilogram per day (mg/kg/day) orally twice daily in 2 equal doses for 12 months. Dosages were adjusted according to trough whole blood level and standard institutional practice. Participants also received mycophenolate mofetil tablet 1 gram orally twice daily (up to 1.5 gram orally twice daily in Black participants) for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg for Months 1 to 6</title>
            <description>CP-690,550 15 milligram (mg) tablet orally twice daily for Month 1 to 6, then 10 mg tablet orally twice daily for Month 7 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 15 mg for Months 1 to 3</title>
            <description>CP-690,550 15 mg tablet orally twice daily for Month 1 to 3, then 10 mg tablet orally twice daily for Month 4 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Dyspepsia Assessment (SODA)</title>
          <description>SODA:17-item health scale, assessed participant-reported perceptions of dyspepsia;consists of 3 subscales:Pain Intensity (6-items to assess pain and intensity of abdominal [Ab] discomfort; Range (Ra):2-47, higher score= greater pain and Ab discomfort), Non-Pain Symptoms (7-items to assess severity and impact of non-pain symptoms:burping/belching,heartburn,bloating,flatulence,sour taste,nausea,and bad breath; Ra:7-35,higher scores = increased symptom severity and influence), and Satisfaction (4-items to assess degree of satisfaction with Ab discomfort; Ra:2-23,higher scores= more satisfaction).</description>
          <population>Data not analyzed since the SODA instrument was found irrelevant in the treated population.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cyclosporine</title>
          <description>Cyclosporine (CsA) microemulsion at a starting dose of 8 to 10 milligram per kilogram per day (mg/kg/day) orally twice daily in 2 equal doses for 12 months. Dosages were adjusted according to trough whole blood level and standard institutional practice. Participants also received mycophenolate mofetil tablet 1 gram orally twice daily (up to 1.5 gram orally twice daily in Black participants) for 12 months.</description>
        </group>
        <group group_id="E2">
          <title>CP-690,550 15 mg for Months 1 to 6</title>
          <description>CP-690,550 15 milligram (mg) tablet orally twice daily for Month 1 to 6, then 10 mg tablet orally twice daily for Month 7 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
        </group>
        <group group_id="E3">
          <title>CP-690,550 15 mg for Months 1 to 3</title>
          <description>CP-690,550 15 mg tablet orally twice daily for Month 1 to 3, then 10 mg tablet orally twice daily for Month 4 to 12. Participants also received mycophenolate mofetil 1 gram tablet orally twice daily for 12 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Aplastic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Electromechanical dissociation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital cystic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness cortical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Brain death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Drug interaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Serum sickness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>BK virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Herpes ophthalmic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Keratitis herpetic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Perinephric abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Peritoneal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Polyomavirus-associated nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Prostatic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Retinitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Tuberculosis gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Urinary tract infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Chronic allograft nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Complications of transplanted kidney</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Graft complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Graft dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Graft loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Perirenal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Post procedural discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Post procedural haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Renal graft loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Renal lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Urethral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Electroencephalogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypercreatininaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Epstein-Barr virus associated lymphoproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hodgkins disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Non-Hodgkins lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Areflexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Haemorrhage urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Renal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Renal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Urinary fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bladder catheter removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Superior vena caval occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Vascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Gingival hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BK virus infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Epstein-Barr viraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Polyomavirus-associated nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Complications of transplant surgery</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Complications of transplanted kidney</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Graft complication</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Post procedural discharge</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Viral test positive</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Penile pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Testicular swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hirsutism</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypertrichosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Incisional drainage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

